June 9, 2023

Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)

Key Points

Key points are not available for this paper at this time.

Abstract

Our study identified signals for DVT with baricitinib, tofacitinib, and upadacitinib. Further research using well-designed epidemiological data is needed to validate these results.

Bookmark

Cite This Study

Mytheen et al. (Fri,) studied this question.

synapsesocial.com/papers/69daa4e785037e71b268458c https://doi.org/https://doi.org/10.1080/14740338.2023.2223955

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Baricitinib plus Remdesivir for Hospitalized Adults with Covid-192020 · 1,915 citations
2Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database.2018 · 5 citations
3Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA2018 · 55 citations
4OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications2016 · 253 citations
5Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?2017 · 104 citations